Eli Lilly and Company
LLYHealthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.
- Revenue
- +38.6%
- EPS
- +16.3%
- Free cash flow
- +21.8%
- Total debt
- +15.0%
Quarter to September 2026, against a year earlier
Follow LLY
Alert me
Eli Lilly and Company 10-Q filed Aug 7, 2025
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 1, 2025: 8 added · 2 removed · 20 modified; 8 with only figures updated
-
Removed · Financial Results
Revenue increased for the three months ended March 31, 2025 driven by increased volume, partially offset by lower realized prices and unfavorable impact of foreign exchange rates. The increase in revenue during the three months ended March 31, 2025 was primarily driven by Mounjaro and Zepbound.